Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge
Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge Yahoo
View ArticleOsiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results
Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results Yahoo/BusinessWire
View ArticleOsiris Wows The Market With Stellar Earnings Report
Osiris Wows The Market With Stellar Earnings Report Seeking Alpha
View ArticlePenny-Wise, Pound-Foolish Stem Cell Stocks
Penny-Wise, Pound-Foolish Stem Cell Stocks Seeking Alpha
View ArticleOsiris - Can Stem Cells Lead To Profits?
Osiris - Can Stem Cells Lead To Profits? Seeking Alpha
View ArticleOsiris Therapeutics pares 2Q loss as sales rise
Osiris Therapeutics pares 2Q loss as sales rise Yahoo/AP
View ArticleOsiris shares rocket, company details Grafix study
Osiris shares rocket, company details Grafix study Yahoo/AP
View Article3 Humongous Health-Care Stocks This Week
3 Humongous Health-Care Stocks This Week Motley Fool
View ArticleA Closer Look at 3 Players in Diabetes Treatments
A Closer Look at 3 Players in Diabetes Treatments Motley Fool
View ArticleBiotech's Falling Fortunes Stymie Osiris' Huge Week
Biotech's Falling Fortunes Stymie Osiris' Huge Week Motley Fool
View Article4 Biotech Stocks Rising on Unusual Volume
4 Biotech Stocks Rising on Unusual Volume TheStreet.com
View Article3 Biotech Products To Watch Over The Next Year
3 Biotech Products To Watch Over The Next Year Seeking Alpha
View ArticleOsiris and FDA Reach Agreement on Regulatory Pathway for Biosurgery Products
Osiris and FDA Reach Agreement on Regulatory Pathway for Biosurgery Products Yahoo
View ArticleThis Biotech Trifecta Could Revolutionize Cancer
This Biotech Trifecta Could Revolutionize Cancer Motley Fool
View ArticleOsiris: Grafix reimbursement won't change for now
Osiris: Grafix reimbursement won't change for now Yahoo/AP
View ArticleAhead of the Bell: Osiris CEO resigns, shares slip
Ahead of the Bell: Osiris CEO resigns, shares slip Yahoo/AP
View ArticleOsiris Therapeutics' Survival In Doubt After Losing 'Pass-Through' Status In...
Osiris Therapeutics' Survival In Doubt After Losing 'Pass-Through' Status In 2015 Seeking Alpha
View Article
